Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
This is the letter, deemed consent for electronic Comms
https://avacta.com/wp-content/uploads/2021/03/260675-Avacta-Deemed-Consent-Letter.pdf
Last 10 mins there has been a little sell pressure but MM's have kept the SP around 178 179 so appears to be some resistance in dropping it lower. The last few days it would have been back to 175 174 almost immediately. Think it could be a good day, be nice to break 180
So overall not a bad week, I felt like there has been a lot of background buying going on and the MM's trying to drop the SP to fill large orders. As a LTH I'm pretty happy with the week. March is getting so much closer to a news rich territory. So what do holders think the next RNS will tell us?
Next week we could definitely see ACTIV2 Pll full and straight into Plll
I have some other ideas but what do you all reckon?
Chi Onwura is a brilliant local MP and has very close ties to Newcastle University Hospital. My wife has an ultra rare kidney condition and Newcastle is the UK (if not Global) centre of excellence for this condition. Chi was involved in securing funding so the centre could be established and also securing NICE funding support for an orphan drug (that's proved to be transformative but is ridiculously expensive because the condition it treats is so rare)
New coronavirus variant in NYC has vaccine-evading mutation.
This is why countries are starting to realise they'll need effective and early treatments alongside vaccine's to combat Covid in the future.
https://www.livescience.com/new-coronavirus-variant-new-york-city.html
A new coronavirus variant with concerning mutations is on the rise in New York City, according to news reports.
This latest coronavirus variant, dubbed B.1.526, first emerged in New York in November 2020, and it now accounts for about 25% of coronavirus genomes that were sequenced from New York in February and posted to a global database called GISAID, according to The New York Times.
Researchers at the California Institute of Technology identified B.1.526 after looking through that database for mutations in the virus's spike protein, or the structure that allows the virus to bind to and enter human cells. The researchers have posted their findings, which have yet to be peer-reviewed, to the preprint database bioRxiv.
Two "branches" or versions of the B.1.526 lineage exist, both with worrisome mutations. One branch has a mutation called E484K, which has also been seen in other coronavirus variants, including those identified in South Africa and Brazil. This mutation may reduce the ability of certain antibodies to neutralize, or inactivate, the virus, and may help the coronavirus partially evade COVID-19 vaccines, Live Science previously reported. The other branch has a mutation called S477N, which may help the virus bind more tightly to cells, the Times reported.
Separately, researchers from Columbia University also identified the B.1.526 variant when they sequenced more than 1,100 virus samples from patients with COVID-19 at their hospital. They found that the percentage of patients infected with the version of B.1.526 with the E484K mutation had increased quite rapidly in recent weeks, and it now infects 12% of their patients.
"We find the rate of detection of this new variant is going up over the past few weeks. A concern is that it might be beginning to overtake other strains, just like the U.K. and South African variants" did in those countries, Dr. David Ho, director of the Aaron Diamond AIDS Research Center at Columbia University who led the Colubmia study, told CNN. However, Ho added that more research is needed to determine if B.1.526 is winning out over other variants.
"Given the involvement of E484K or S477N [mutations], combined with the fact that the New York region has a lot of standing immunity [to earlier coronavirus strains] from the spring wave, this is definitely one to watch," Kristian Andersen, a virologist at the Scripps Research Institute in San Diego, told the Times.
Agree no trading for me, if I can survive the Nov/Dec battering then I'll do what I did then and keep topping up if the price suits. There are also quite a few reasons that I believe news could drop at any time...
- 5 weeks post Home Trial finish so they've had access to the data now for a week and will start to discuss the new findings with the various drug approval authorities.
- data monitoring committee for ACTIV2 means people are already looking at the data as it comes in
- Activ2 has circa 100 clinic locations and with just 200 patients for Pll, this could fill at anytime. ACTIV2 is designed to roll seamlessly from Phase ll into Phase lll so we could get news on that at any time. - The company could announce additional news that we are not aware off at any time, one bit could be confirmed manufacturing scale up
- the science keeps telling us that this treatment should work and should be very effective
- there appears to have been a lot of background buying over the last few weeks...WHY????
GLA DYOR
Sorry unfortunately I missed some of it as was remote and my internet went down. Sounds like he covered quite a bit. The big statement being. The world needs an effective early therapeutic.
Found it thanks http://www.ersnet.org/events/the-virus-that-changed-medicine/ is the link
Also remember it well, had been into SNG for only 5 weeks and was camping with friends. A good friend also bought into Avacta on the back of chats over beers that night.
Best of luck for next week to all the AVCT holders. It should certainly be interesting, personally, I'm in AVCT for the long term. Hopefully good news next week will allow Avacta to accelerate the Cancer Programme because that is where the real rewards are.
Guess you didn't look on the church page? The link goes to an event page which has been organised by this church. The NIH had tweeted the link to this page earlier today. The event is called
Emerging Perspectives on the COVID Pandemic
Might be worth tuning in this evening at 8PM UK time
Tune in today at 3 p.m. ET to hear NIMHD Director Dr. PĂ©rez-Stable discuss what you need to know about the COVID-19 vaccine, ClinicalTrials, & more from @nih
Join him & others via Zoom or phone to get the latest #COVID19 update! #ConquerCOVID19 #NIHCEAL
https://bit.ly/37nfrfa
Zoom Webinar ID: 851 2249 0560